TQ Quiz | Metabolic Diseases: Updates and Systemic Interventions (Pittsburgh 2026)

"*" indicates required fields

This field is hidden when viewing the form

Date (Hidden)

MM slash DD slash YYYY

This field is hidden when viewing the form

Event Date (Hidden)

MM slash DD slash YYYY

This field is hidden when viewing the form

Event 90 days past date (Hidden)

MM slash DD slash YYYY

This field is hidden when viewing the form

Event Date Difference (Hidden)

1. Which of the following agents is a Glucagon-Like Peptide 1-Receptor Agonist (GLP1-RA) AND a Glucose Insulinotropic Peptide (GIP) Agonist?*

A - Metformin (Glucophage)

B - Semaglutide (Ozempic)

C - Tirzepatide (Mounjaro)

D - Glimepiride (Amaryl)

2. Which of the following agents is available under the brand name “Wegovy” for weight loss?*

A - Metformin (Glucophage)

B - Semaglutide (Ozempic)

C - Tirzepatide (Mounjaro)

D - Glimepiride (Amaryl)

3. Which of the following agents is a biguanide agent used in the treatment of diabetes?*

A - Metformin (Glucophage)

B - Semaglutide (Ozempic)

C - Tirzepatide (Mounjaro)

D - Glimepiride (Amaryl)

4. Which of the following agents is a sulfonylurea used in the treatment of type 2 diabetes?*

A - Metformin (Glucophage)

B - Semaglutide (Ozempic)

C - Tirzepatide (Mounjaro)

D - Glimepiride (Amaryl)

5. Which of the following classes may cause a transient worsening of diabetic retinopathy in some patients?*

A - Biguanides

B - GLP1-Receptor Agonists

C - Diuretics

D - Beta blockers

6. Which of the following classes may cause a non-arteritic ischemic optic neuropathy (NAION) in some patients?*

A - Biguanides

B - Acetaminophen

C - Insulin

D - GLP1-Receptor Agonists

7. Which of the following side effects is NOT one that is seen in patients using Glucagon-Like Peptide 1-Receptor Agonists (GLP1-RA) AND a Glucose Insulinotropic Peptide (GIP) Agonists (ex. semaglutide, etc.)?*

A - Gain of skeletal muscle mass

B - Loss of skeletal muscle mass

C - Gallbladder issues

D - Gastrointestinal problems (“frozen gut”)

8. Which of the following is a contraindication for use of a Glucagon-Like Peptide 1-Receptor Agonists (GLP1-RA) AND a Glucose Insulinotropic Peptide (GIP) Agonists in patients?*

A - Hypothyroidism

B - Medullary thyroid cancer

C - Obesity

D - Age

9. Increasing which system seems to be most beneficial in patients with Type 2 diabetes and/or obesity?*

A - Pancreatic function

B - Cardiac function

C - Thyroid system

D - Incretin system

10. Which of the following is a proposed or actual benefit for using Glucagon-Like Peptide 1-Receptor Agonists (GLP1-RA) AND a Glucose Insulinotropic Peptide (GIP) Agonists in patients?*

A - Anti-cancer benefits

B - Weight loss benefits

C - Longevity benefits

D - All of the above

11. Which of the following increase the risk of NAION in patients taking a GLP-1 receptor agonist?*

A - Diabetes mellitus

B - Poorly controlled diabetes mellitus

C - Small cup to disc ratio

D - All of the above increase the risk of NAION

12. Which of the following diseases/conditions is most likely to be caused by chronic inflammation?*

A - Pneumonia

B - Strep throat

C - Autoimmune disease

D - A healthy heart

13. Which is least likely to increase oxidative stress (reactive oxygen species)?*

A - Smoking

B - Fruit and vegetable consumption

C - Air pollution

D - Alcohol consumption

14. Which of the following is not part of metabolic syndrome?*

A - Obesity

B - High HDL cholesterol

C - High triglycerides

D - Insulin resistance

15. In Type 2 diabetes, the primary dysfunction is typically ______________.*

A - Insulin resistance

B - Hepatobiliary dysfunction

C - Hypertriglyceridemia

D - Atrial fibrillation

16. “Incretin mimetics” are also known as ___________.*

A - Biguanides

B - Sulfonylureas

C - Insulin

D - GLP1 receptor agonists

17. Tirzepatide (Mounjaro/Zepbound) may be better tolerated and more effective than semaglutide (Ozempic/Wegovy) because it also increases ______.*

A - Glucose insulinotropic polypeptide (GIP)

B - Glucagon-like peptide 1 (GLP1)

C - Insulin resistance

D - Serum triglycerides

18. Which of the following has been associated with a worsening of diabetic retinopathy?*

A - Insulin

B - Sulfonylureas

C - GLP-1 receptor agonists

D - All of the above

19. What is the likely mechanism of the transient worsening of diabetic retinopathy?*

A - Rapid drop in blood glucose

B - Rapid drop in blood pressure

C - Rapid drop in HDL cholesterol

D - Rapid drop in serum insulin

20. Which of the following agents is a sodium-glucose co-transporter 2(SGLT2) inhibitor?*

A - Metformin (Glucophage)

B - Empagliflozin (Jardiance)

C - Tirzepatide (Mounjaro)

D - Glimepiride (Amaryl)

Personal Information

Name*

First Last

Email*

Phone*

OE Tracker #

License #

Address*

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Payment Information

Promotional Code

Pittsburgh 2026 - Metabolic Diseases: Updates and Systemic Interventions*

After 90 days, pricing will increase to $30.

Price:

Retake Discount

Price:

Promotional Discount

Price:

Credit Card*

This field is hidden when viewing the form

Course Information (HIDDEN)

This field is hidden when viewing the form

Course Name (HIDDEN)

This field is hidden when viewing the form

Retake Code (HIDDEN)

This field is hidden when viewing the form

Quiz URL (HIDDEN)

Do not include ending backslash (aka no .com/)

This field is hidden when viewing the form

CE Hours

TQ Quiz | Metabolic Diseases: Updates and Systemic Interventions (Pittsburgh 2026)

Personal Information

Payment Information

Course Information (HIDDEN)

Submit a Comment Cancel reply

Upcoming Conferences

Case Challenges

Case Challenges

TQ Quiz | Metabolic Diseases: Updates and Systemic Interventions (Pittsburgh 2026)

Personal Information

Payment Information

Course Information (HIDDEN)

Submit a Comment Cancel reply

Upcoming Conferences

Case Challenges

Case Challenges

Subscribe For Event Updates